Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Use of Extremophile Bacterium XT1 in Biological Approach to Promote Plant Growth and Tackle Pathogens

Objetivo

Securing sustainable food production whilst preserving ecosystem services has become imperative following the growing trend of population and the increasing need in environment protection. Traditional agricultural methods are called to introduce changes to meet these challenges.
One of the main threats posed to global food security is plant diseases, commonly treated with chemicals responsible for toxic effects and biodiversity disorders.
The present project proposes XTOnE, an organic alternative to chemicals based on the patented extremophile bacterium XT1, whose innovative concept lies on the unique characteristics of this microorganism. XT1 enables induced mechanisms in plants raising self-defense against external pathogens and stresses, stimulating nutrition efficiency and uptake and improving growth and quality.
The expected outcome is a product that acts contemporarily as biostimulant, biofertiliser and organic pest controller whose benefits on plants are preserved even in extreme conditions.
XTOnE addresses the need of farmers by guaranteeing a plant protection throughout the entire life-cycle and reducing losses. It can be grown into organic wastes allowing the reuse of leftovers and unlocking the agriculture potential in delivering the objectives of the Circular Economy.
Its first application will be against a worldwide fungal disease, Verticillium, attacking more than 200 species and affecting especially Europe. XTOnE raised the interest of companies with a European and International presence, due to the lacking of similar solution. Thanks to its easy-of-use and affordable price, it projected to have European and global commercial potential.
In the Feasibility Study, Xtrem Biotech aims to assess the end users’ requirements and the innovation’s economic benefits. The best regulatory and protection roadmap will be defined together with the associated activities to be developed through a potential Phase 2 funding for ensuring the commercialization.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

SME-1 - SME instrument phase 1

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-SMEInst-2016-2017

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

XTREM BIOTECH SL
Aportación neta de la UEn
€ 50 000,00
Dirección
AVENIDA DEL CONOCIMIENTO 1 EDIFICIO BIC ESC 4 PLANTA 1 PUERTA A
18016 GRANADA
España
Pyme
Sí
Región
Sur Andalucía Granada
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00